These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35878189)

  • 81. Spasmodic Dysphonia.
    Lin J; Sadoughi B
    Adv Otorhinolaryngol; 2020; 85():133-143. PubMed ID: 33166970
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Spasmodic Dysphonia Patients' Perception of Pain with Botulinum Toxin Injections.
    Heffernan A; Hu A
    Laryngoscope; 2024 Jan; 134(1):240-246. PubMed ID: 37409790
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Socioeconomic Variables of Patients with Spasmodic Dysphonia: A Preliminary Study.
    O'Connell Ferster AP; Sataloff RT; Shewokis PA; Hu A
    J Voice; 2018 Jul; 32(4):479-483. PubMed ID: 28927659
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia.
    Bielamowicz S; Ludlow CL
    Ann Otol Rhinol Laryngol; 2000 Feb; 109(2):194-203. PubMed ID: 10685573
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series.
    Blitzer A
    Eur J Neurol; 2010 Jul; 17 Suppl 1():28-30. PubMed ID: 20590805
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
    Lerner MZ; Lerner BA; Patel AA; Blitzer A
    Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Botulinum toxin in the treatment of adductor spasmodic dysphonia.
    Thompson AR
    J Ark Med Soc; 1994 Jan; 90(8):383-5. PubMed ID: 8175618
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy.
    Murry T; Woodson GE
    J Voice; 1995 Dec; 9(4):460-5. PubMed ID: 8574315
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Bilateral Vocal Fold Medialization: A Treatment for Abductor Spasmodic Dysphonia.
    Dewan K; Berke GS
    J Voice; 2019 Jan; 33(1):45-48. PubMed ID: 29132808
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Perceptual analyses of spasmodic dysphonia before and after treatment.
    Cannito MP; Woodson GE; Murry T; Bender B
    Arch Otolaryngol Head Neck Surg; 2004 Dec; 130(12):1393-9. PubMed ID: 15611398
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Treatment for spasmodic dysphonia: limitations of current approaches.
    Ludlow CL
    Curr Opin Otolaryngol Head Neck Surg; 2009 Jun; 17(3):160-5. PubMed ID: 19337127
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Influence of consonant voicing characteristics on sentence production in abductor versus adductor spasmodic dysphonia.
    Cannito MP; Chorna LB; Kahane JC; Dworkin JP
    J Voice; 2014 May; 28(3):394.e13-22. PubMed ID: 24440058
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Voice Onset Time for the Word-Initial Voiceless Consonant /t/ in Japanese Spasmodic Dysphonia-A Comparison With Normal Controls.
    Yanagida S; Nishizawa N; Mizoguchi K; Hatakeyama H; Fukuda S
    J Voice; 2015 Jul; 29(4):450-4. PubMed ID: 25944292
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Effects of type II thyroplasty on adductor spasmodic dysphonia.
    Sanuki T; Yumoto E; Minoda R; Kodama N
    Otolaryngol Head Neck Surg; 2010 Apr; 142(4):540-6. PubMed ID: 20304275
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Long-term voice handicap index after type II thyroplasty using titanium bridges for adductor spasmodic dysphonia.
    Sanuki T; Yumoto E; Kodama N; Minoda R; Kumai Y
    Auris Nasus Larynx; 2014 Jun; 41(3):285-9. PubMed ID: 24369905
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Analysis of factors affecting botulinum toxin results in spasmodic dysphonia.
    Inagi K; Ford CN; Bless DM; Heisey D
    J Voice; 1996 Sep; 10(3):306-13. PubMed ID: 8865102
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Management of supraglottic squeeze in adductor spasmodic dysphonia: a new technique.
    Young N; Blitzer A
    Laryngoscope; 2007 Nov; 117(11):2082-4. PubMed ID: 17828055
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Botulinum toxin efficacy in the treatment of patients with spasmodic dysphonia].
    Svetel M; Vasić M; Tomić G; Stanković P; Stojanović M; Dragasević N; Dergenc R; Vukasinović M; Pekmezović T; Petrović I; Kostić V
    Vojnosanit Pregl; 2007 Oct; 64(10):671-5. PubMed ID: 18041568
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
    Sulica L; Blitzer A; Brin MF; Stewart CF
    Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.